Wang, Xiaoyong
Jemaa, Skander
Fredrickson, Jill
Coimbra, Alexandre Fernandez
Nielsen, Tina
De Crespigny, Alex
Bengtsson, Thomas
Carano, Richard A. D.
Article History
Received: 14 July 2021
Accepted: 22 March 2022
First Online: 30 March 2022
Declarations
:
: This is a retrospective analysis of two multi-institutional clinical trials (NCT0128774, NCT02500407). The trials were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice guidelines. The trials protocol approval was obtained from the ethics committee/institutional review board at each participating institution, and written informed consent to participate was provided by all patients. The retrospective analysis of this data presented in this manuscript was approved by Genentech Data Governance Committee (Genentech Inc) and is consistent with the intended use of this data defined by the original ethics committee/institutional review board at each participating institution and the written informed consent provided by all patients.
: Not applicable.
: The only potential conflicts of interest that may be relevant is that all authors are employees and stockholders in Roche/Genentech.